nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Addiction/Reward"

 

FDA Allows Marketing of Device to Curb Opioid-Withdrawal Symptoms
November 22, 2017   

The US Food and Drug Administration (FDA) has granted marketing authorization for an electric stimulation device to be used in the reduction of symptoms related to opioid withdrawal...
 Continue reading
Drinking in Adolescence May Alter Brain Development
November 20, 2017   

A recent study found initiating drinking during adolescence was associated with disordered normal brain growth trajectories....
 Continue reading
Increased Risk of Opioid-Related Death in Patients Taking Concomitant Gabapentin
October 16, 2017   

A new study examined the increased risk for opioid-related death in patients taking concomitant prescription opioids and gabapentin...
 Continue reading (Members only)
FDA Permits Marketing of Mobile Medical Application for Substance Use Disorders
September 20, 2017   

The US FDA has permitted the marketing of the Reset device, the first mobile medical application to help treat substance use disorders...
 Continue reading
Evaluating the Evidence for Cannabis as a Therapeutic Option: Focus on Chronic Pain and PTSD
September 7, 2017   

As the medicinal use of cannabis becomes increasingly accepted and legal--at least at the state level--a major concern for the medical community is: what is the evidence regarding the efficacy and safety of cannabis as a treatment for medical and psychiatric disorders? Two recent reviews, commissioned by the Veterans Health Administration and funded by the US Department of Veterans Affairs, addressed this issue specifically for chonic pain and posttraumatic stress disorder (PTSD)...
 Continue reading
Cannabis Use, Medication Non-Adherence, and Psychosis Relapse
August 4, 2017   

New research shows that cannabis use by patients with psychosis is linked to a significantly increased risk for psychosis relapse. That increase in risk for relapse may be directly due to non-adherence to antipsychotic medication...
 Continue reading (Members only)
Controlling Pain Without Medication: Mindfulness-Oriented Recovery Enhancement (MORE)
July 7, 2017   

Long-term opioid use may lead to an increased risk of aberrant-medication related behaviors among patients who suffer from chronic pain. Risk of opioid misuse and addiction is a growing concern, but a new approach may prove to help patients suffering from both chronic pain and opioid misuse....
 Continue reading
Update on Substance Abuse and Addictions
June 26, 2017   

At the recent 2017 American Psychiatric Association (APA) Annual Meeting, the topic of substance abuse and addiction was the focus of several sessions, lectures, and posters. Some of the highlights from the conference include...
 Continue reading
Highlights from the 2017 APA Annual Meeting
June 8, 2017   

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.
 Continue reading
Report on Health Effects of Cannabis Released by National Academies of Sciences, Engineering, and Medicine
February 3, 2017   

With the recent legalization of both medical and recreational use in numerous states across the nation (and an estimated 22 million cannabis users in the United States), there is growing interest regarding the potential benefits and risks associated with marijuana use. It is therefore apropos that the Committee on the Health Effects of Marijuana (as part of the National Academies of Sciences, Engineering, and Medicine) has published a report that reviews the state of existing evidence on both the positive and negative effects of marijuana as well as recommendations for future research...
 Continue reading (Members only)
1234
Top of Page